The only FDA-approved peptide for women's sexual desire. PT-141 (Vyleesi) treats hypoactive sexual desire disorder in premenopausal women.
Sexual wellness is one of the most under-discussed areas of women's health — and it's where peptide therapy has produced its most definitive result for women. PT-141 (bremelanotide), marketed as Vyleesi, is the only peptide with an FDA-approved indication specifically for women. It treats hypoactive sexual desire disorder (HSDD), a condition affecting an estimated 1 in 10 premenopausal women, by acting on the brain's melanocortin pathways rather than vascular mechanisms.
FDA-approved for HSDD in premenopausal women. Acts on brain melanocortin receptors to restore desire — not just blood flow.
Shop at BioPure → Read Full Profile →Upstream hormonal support. Controls the GnRH cascade governing reproductive hormones and may support overall sexual health.
Shop at BioPure → Read Full Profile →Every woman's situation is different. Your life stage, specific symptoms, medical history, and treatment goals all factor into which peptide — or combination of peptides — may be most relevant. We always recommend working with a licensed healthcare provider who has experience with peptide therapy.
Our quiz can help narrow down options based on your individual profile:
Take the Quiz →Medical Disclaimer: This guide is for educational purposes only. It is not medical advice or a treatment recommendation. Peptide therapies discussed may be investigational, off-label, or subject to evolving FDA regulations. Always consult a qualified healthcare provider.
Affiliate Disclosure: Vendor links are affiliate partnerships. Full disclosure →
Peptide therapy spans hormones, weight, skin, gut health, mood, energy, and recovery.
View All Use Cases →